Midland Commences an Exploration Program for Copper-Gold-Molybdenum-Silver Occurrences on the Saruman Project
MDMONTREAL, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to report the start of an exploration program to follow up on the 2024 copper-gold-molybdenum-silver (Cu-Au-Mo-Ag) occurrences identified on its Saruman project. Located in the Eeyou Istchee James Bay region, approximately 75 kilometres north of the Troilus Gold Corp. copper-gold (Cu-Au) project, the Saruman project was acquired by map designation in November 2023, is wholly owned by Midland and consists of 121 claims covering a surface area of 64 square kilometres.
UBS Maintains Neutral on Pediatrix Medical Group, Lowers Price Target to $16
MDExpert Outlook: Pediatrix Medical Group Through The Eyes Of 4 Analysts
MDMacquarie Maintains Outperform on Pediatrix Medical Group, Raises Price Target to $20
MDPediatrix Medical Group Q1 Adj. EPS $0.33 Beats $0.24 Estimate, Sales $458.36M Beat $451.50M Estimate
MDTruist Securities Maintains Hold on Pediatrix Medical Group, Lowers Price Target to $16
MDUBS Maintains Neutral on Pediatrix Medical Group, Raises Price Target to $18.5
MDTruist Securities Maintains Hold on Pediatrix Medical Group, Raises Price Target to $18
MDPediatrix Q4 Beats Estimates As Operational Improvements Drive Performance
MDPediatrix Medical reported Q4 revenue of $502.36 million, surpassing estimates, with adjusted EPS of $0.51. The company projects 2025 adjusted EBITDA of $215 million–$235 million.
Pediatrix Medical Anticipates 2025 Adjusted EBITDA Of $215M-$235M
MDPediatrix Medical Group Q4 2024 Adj EPS $0.51 Beats $0.37 Estimate, Sales $502.36M Beat $486.21M Estimate
MDPediatrix Medical Expects To Hit The Upper End Of Its Projected Range For 2024 Adjusted Ebitda And Could Even Surpass It. The Company Previously Forecasted Adjusted EBITDA Of $205M-$215M For 2024 And Now Believes It Is On Track To Exceed Those Expectation
MDPediatrix Medical Has Appointed Executive Chair Mark Ordan To Return To His Former Position As CEO, Effective Immediately, Replacing James Swift Who Assumed The CEO Role In January 2023
MDMizuho Maintains Neutral on Pediatrix Medical Group, Raises Price Target to $15
MDUBS Maintains Neutral on Pediatrix Medical Group, Raises Price Target to $16.5
MDPeeling Back The Layers: Exploring Pediatrix Medical Group Through Analyst Insights
MDDeutsche Bank Maintains Hold on Pediatrix Medical Group, Raises Price Target to $15
MDTruist Securities Maintains Hold on Pediatrix Medical Group, Raises Price Target to $16
MDMizuho Maintains Neutral on Pediatrix Medical Group, Raises Price Target to $15
MDPediatrix Medical Group Q3 2024 Adj EPS $0.44 Beats $0.37 Estimate, Sales $511.16M Beat $498.87M Estimate
MDWhere Mednax Stands With Analysts
MDMednax (NYSE:MD) has observed the following analyst ratings within the last quarter:
Credit Suisse Maintains Outperform on Mednax, Lowers Price Target to $30
MDLooking Into Mednax's Return On Capital Employed
MDMednax (NYSE:MD) brought in sales totaling $482.23 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 144.61%, resulting in a loss of $21.19 million.
Mizuho Maintains Neutral on Mednax, Lowers Price Target to $23
MDRecap: Mednax Q1 Earnings
MDMednax (NYSE:MD) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:00 AM.
Here's what investors need to know about the announcement.
Earnings
Mednax beat estimated earnings by 22.22%, reporting an EPS of $0.33 versus an estimate of $0.27.
Mednax Q1 EPS $0.33 Beats $0.27 Estimate, Sales $482.23M Beat $472.46M Estimate
MD